Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Slides:



Advertisements
Similar presentations
Development and Utilization of Drug For Treating Psychotic Disorders: How Well Have US Federal and State Policies/ Laws Served Individual and Societal.
Advertisements

Adapted from: Treatment of Schizophrenia (and Related Psychotic Disorders) Scott Stroup, MD, MPH 2004.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 31 Antipsychotic Agents and Their Use in Schizophrenia.
Antipsychotic Drugs Joseph De Soto MD, PhD, FAIC.
1 Post-marketing review of Movement Disorders and Neuroleptic Malignant Syndrome associated with metoclopramide Mary Ross Southworth, PharmD Safety Evaluator,
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 16Psychopharmacology.
ANTIPSYCHOTIC. What do antipsychotics treat?  Psychotic Disorders (Psychosis) Abnormal Thinking and Perceptions Loss of Contact with Reality Delusions.
Pharmacotherapy in Psychotic Disorders. Antipsychotic drugs Treat the symptoms of the disorder Do not cure schizophrenia Include two major classes: –
Alan Breier, M.D. Leader, Zyprexa Product Team Lilly Research Fellow Professor of Psychiatry, Indiana University School of Medicine Adjunct Associate of.
Medical Care. Antipsychotic medications mainstay of treatment for schizophrenia 2 Types of Antipsychotics Conventional or 1 st generation – Dopamine 2.
Medication Induced Movement Disorders Jacob Alexander July 2012 Rural & Remote Mental Health Service.
Schizophrenia characterized by positive and negative symptoms –positive symptoms – those that can be observed; ex. hallucinations –negative symptoms –
Antipsychotic agents By S.Bohlooli PhD.
ATYPICAL ANTIPSYCHOTICS FIRST GENERATION ANTIPSYCHOTICS.
بسم الله الرحمن الرحيم Dr: Samah Gaafar Hassan Al-shaygi.
0 Extra pyramidal side effects & NMS in older patients Prepared by Bryan McMinn Clinical Nurse Consultant Mental Health Nursing of Older People 31 January.
Drugs Used for Psychoses Chapter 18 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
for MHD & Therapeutics is proud to present And Now Here Is The Host... Dr. Schilling.
UNIT 4 TREATMENTS FOR SCHIZOPHRENIA. WHY DO WE NEED TO TREAT ABNORMALITY? 1) How do we define abnormality? Failure to function adequately Deviation from.
Copyright © 2016 by Elsevier, Inc. All rights reserved. Geropharmacology.
抗精神失常药 PHARMACOLOGY OF ANTIPSYCHOTIC DRUGS (NEUROLEPTICS)
抗精神失常药 PHARMACOLOGY OF ANTIPSYCHOTIC DRUGS (NEUROLEPTICS)
Introduction. Practical Perspectives in the Surgical Management of Parkinson Disease: LCIG.
Agitation Medication  Side Effects Follow Up and Documentation
Let’s Talk About Side Effects: Benefits and Risks of Mental Illness Medication ©2017 Neurocrine Biosciences, Inc. All Rights Reserved. CP-TD-US /17.
Seema Jain1, Rebecca Andridge2, Jessica Hellings3
Antipsychotic Agents and Their Use in Schizophrenia
11 Drugs for Psychoses.
Antipsychotic-Induced Dysphagia
PSY 6669 Behavioral Pathology
Current Management and Future Options for Tardive Dyskinesia
Why New Treatments for Schizophrenia Should Be on Your Radar
Antipsychotic Agents and Their Use in Schizophrenia
5 Things NPs and PAs Need to Know About Tardive Dyskinesia
What Is Major Depressive Disorder (MDD)?
Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.
الصحة النفسية والعقلية
Drug-induced dyskinesias
The Patient Journey to Remission in MDD: A Collaborative Approach
Differentiating Drug-Seeking Behavior From Poorly Controlled Pain
Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies.
Case Challenges in Chronic Migraine
The Parkinson's Disease Psychosis Journal Club
Are We Closer to Personalized Medicine in MS?
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Schizophrenia: brain chemicals
Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia
Antipsychotics: The Essentials Module 4: Adverse Effects Neuroleptic Malignant Syndrome Flavio Guzmán, MD.
Insights Into the Spectrum of Tardive Dyskinesia
Impactful Data in TD That Can Guide Treatment Decisions
Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.
Best Practices in the Identification and Management of Alzheimer Agitation.
Treatment-Resistant Schizophrenia
Tackling Schizophrenia With Your Patients
Challenging Questions in Huntington Chorea
The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.
The Psychiatrist's Role in Tardive Dyskinesia
New Age Antipsychotic: Iloperidone
Communicating With Your Patients About Major Depressive Disorder
Neuroleptic drugs.
The Psychiatrist's Role in Tardive Dyskinesia
The ABCs of Diagnosing Tardive Dyskinesia
Volume 29, Issue 1, Pages (February 2011)
Addressing Cardiovascular Events:
Antipsychotics.
Binge Eating Disorder.
Tardive Dyskinesia 101.
Expert Insights in Diagnosis and Management of Common Drug-Induced Movement Disorders.
Risk Stratification in MDS
Conceptual diagram of dopaminergic system and disease and drug effects
Presentation transcript:

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia

Drug-Induced Movement Disorders

Appropriate Use of Antipsychotic Agents

EPS

Acute Dystonia

Acute Akathisia

Drug-Induced Parkinsonism

Neuroleptic Malignant Syndrome

Tardive Syndromes

Movement Disorders in Untreated Patients With Schizophrenia

TD

Differential Diagnosis

Epidemiology of TD

Risk Factors for TD

Monitoring Movement Disorders in Patients Taking Antipsychotics

Rating Scales

Schooler-Kane Research Criteria for TD Diagnosis

Treatment of TD

Other Treatments Used

Agents in Development

Deutetrabenazine vs Placebo

Deutetrabenazine AEs

Valbenazine vs Placebo

Valbenazine AEs

Conclusions

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.